Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3446138 | 1.00 | PPARG (0.49) | PPARG | |
| SCHEMBL7860612 | 1.00 | PPARG (0.49) | PPARG | |
| SCHEMBL13292113 | 0.91 | PPARG (0.55) | PPARG | |
| SCHEMBL13813444 | 0.91 | PPARG (0.55) | PPARG | |
| SCHEMBL12798079 | 0.91 | PPARG (0.55) | PPARG | |
| SCHEMBL19394016 | 0.91 | PPARG (0.55) | PPARG | |
| SCHEMBL12798082 | 0.91 | PPARG (0.55) | PPARG | |
| SCHEMBL9680026 | 0.89 | PPARG (0.61) | PPARG | |
| Verbalactone SCHEMBL18529435 | 0.89 | PPARG (0.61) | PPARG | |
| SCHEMBL9681220 | 0.89 | PPARG (0.61) | PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9656990-B2 | Cathepsin cysteine protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9573913-B2 | Cathepsin cysteine protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20160355502-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160311791-A1 | NOVEL TRICYCLIC CALCIUM SENSING RECEPTOR ANTOGONISTS FOR THE TREATMENT OF OSTEOPOSOSIS | MERCK SHARP & DOHME CORP. (US) | 2016-10-27 | — | — | US | disclosed |
| US-9458181-B2 | Cathepsin cysteine protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160244417-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-08-25 | — | — | US | disclosed |
| US-20150250759-A1 | COMPOSITION FOR INHIBITION OF CATHEPSIN K | MERCK SHARP & DOHME CORP. (US) | 2015-09-10 | — | — | US | disclosed |
| US-20150099719-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK SHARP & DOHME LLC | 2015-04-09 | — | — | US | disclosed |
| US-20140256743-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2014-09-11 | — | — | US | disclosed |
| US-8791162-B2 | Cathepsin cysteine protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-07-29 | — | — | US | disclosed |
| US-7244723-B2 | Substituted furopyrimidinones as a mitotic kinesin inhibitors | MERCK & CO., INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070149536-A1 | Inhibitors of Akt activity | MERCK SHARP & DOHME CORP. | 2007-06-28 | — | — | US | disclosed |
| US-7235580-B2 | Mitotic kinesin inhibitors | MERCK & CO., INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-20070142388-A1 | Inhibitors of Akt activity | MERCK SHARP & DOHME CORP. | 2007-06-21 | — | — | US | disclosed |
| US-20070134660-A1 | Methods for identifying modulators of kinesin activity | ROSETTA INPHARMATICS LLC (US) | 2007-06-14 | — | — | US | disclosed |
| US-7223738-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20070099880-A1 | Estrogen receptor modulators | MERCK SHARP & DOHME CORP. | 2007-05-03 | — | — | US | disclosed |
| US-20070099893-A1 | Cathepsin cysteine protease inhibitors | MERCK CANADA INC. (CA) | 2007-05-03 | — | — | US | disclosed |
| US-7186723-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-20060111440-A1 | Cathepsin cysteine protease inhibitors | MERCK CANADA INC. (CA) | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149536-A1 | Inhibitors of Akt activity | AKT1, AKT2, AKT3 | PPARG 4465/4885 |
| US-20140256743-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | CTSB, CTSS, CTSZ | PPARG 2766/4885 |
| US-20160311791-A1 | NOVEL TRICYCLIC CALCIUM SENSING RECEPTOR ANTOGONISTS FOR THE TREATMENT OF OSTEOPOSOSIS | CASR, CALCR, CALCRL | PPARG 804/4885 |
| US-20070099893-A1 | Cathepsin cysteine protease inhibitors | CTSB, CTSS, CTSZ | PPARG 2766/4885 |
| US-20160355502-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | CTSB, CTSS, CTSZ | PPARG 2766/4885 |
| US-20160244417-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | CTSB, CTSS, CTSZ | PPARG 2766/4885 |
| US-20060111440-A1 | Cathepsin cysteine protease inhibitors | CTSB, CTSS, CTSZ | PPARG 2766/4885 |
| US-20070142388-A1 | Inhibitors of Akt activity | AKT2, AKT1, AKT3 | PPARG 4354/4885 |
| US-20150250759-A1 | COMPOSITION FOR INHIBITION OF CATHEPSIN K | CTSK, CTSB, CTSZ | PPARG 2655/4885 |
| US-20070134660-A1 | Methods for identifying modulators of kinesin activity | KIF2C, KIF5B, KIF15 | PPARG 4389/4885 |
| US-20070099880-A1 | Estrogen receptor modulators | ESR2, GPER1, ESRRA | PPARG 112/4885 |
| US-20150099719-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | CTSB, CTSS, CTSZ | PPARG 2766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.